FM
HRMY icon

Foster & Motley’s Harmony Biosciences HRMY Stock Holding History

Foster & Motley’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$687K Sell
18,867
-5,414
-22% -$171K 0.03% 280
2026
Q1 		$680K Buy
24,281
+1,072
+5% +$35.2K 0.04% 271
2025
Q4 		$868K Sell
23,209
-1,225
-5% -$40.3K 0.05% 245
2025
Q3 		$673K Sell
24,434
-856
-3% -$29.5K 0.04% 264
2025
Q2 		$799K Buy
25,290
+14,731
+140% +$474K 0.05% 240
2025
Q1 		$350K Buy
+10,559
New +$379K 0.02% 317

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Foster & Motley's HRMY Position: Q2 2026 in Review

Foster & Motley reduced its Harmony Biosciences (HRMY) stake by 22% in Q2 2026, selling an estimated $171K and leaving 18,867 shares worth $687K. The position accounts for 0.03% of the portfolio, ranked #280.

Foster & Motley first reported a position in HRMY in Q1 2025 and has held it in 6 quarters since. The position peaked at $868K in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Foster & Motley held 18,867 shares of Harmony Biosciences worth $687K as of Q2 2026.
  • Foster & Motley sold 5,414 Harmony Biosciences shares in Q2 2026, an estimated $171K.
  • Harmony Biosciences made up 0.03% of Foster & Motley's portfolio in Q2 2026, its #280 holding.
  • Foster & Motley first reported a position in Harmony Biosciences in Q1 2025 and has held it in 6 quarters since.
  • Foster & Motley's Harmony Biosciences position peaked at $868K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Foster & Motley's 13F filing for Q2 2026, filed 7 Aug 2026.